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26.1  Introduction
26.1.1  Definition and Types of Cutaneous 
Adverse Drug Reactions
A CADR is a skin eruption induced by drugs, systemic 
or topical drugs, used in adequate doses and in the cor-
rect indications. CADRs are a frequent problem in 
Dermatology, but their incidence is not exactly known; 
1–5% of inpatients experience such a reaction and it is 
a frequent cause of consultation in Dermatology [1–5]. 
Most CADRs are mild, but about 20% can be severe 
and require hospitalization, for example, in patients 
with drug hypersensitivity syndrome/drug reaction 
with eosinophilia and systemic symptoms (DRESS) 
and toxic epidermal necrolysis which, apart from the 
skin, have involvement of other organs [5].
Considering its pathomechanism, CADRs can be 
divided into several types. Most cases belong to type 
A and C, predictable and chemical, which represent 
an exaggerated pharmacologic activity of the drug, 
such as cheilitis from isotretinoin, or xerosis and 
 papulo-pustulo-follicular reactions from inhibitors of 
epidermal growth factor receptor [6]. They can be 
enhanced by modification of drug bioavailability due 
to drug interactions, reduced metabolization, or elimi-
nation, especially in genetically susceptible individu-
als. Type D includes late (delayed) reactions, such as 
teratogenesis or carcinogenesis, and type E results 
from end-of-dose reactions [7]. Type B reactions are 
idiosyncratic, unexpected, unpredictable, and among 
these, many are due to immune reactions induced by 
the drug [5] (Table 26.1).
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26.1.2  Main Clinical Patterns  
of Immune-Mediated CADRs
Systemic exposure to drugs can sensitize the individual 
and lead to a wide variety of CADRs or drug eruptions. 
Some reactions are not specifically induced by a drug, 
such as a maculopapular exanthema, urticaria or angioe-
dema, lichenoid reaction, or subacute lupus erythema-
tosus. Other patterns are almost exclusively induced by 
drugs (>90%), such as Stevens–Johnson syndrome, 
toxic epidermal necrolysis, fixed drug eruption, and 
acute generalized exanthematous pustulosis [5, 8].
According to their time course, drug eruptions 
can be divided into immediate reactions, occurring 
within minutes to 1–2 h of drug intake, and delayed 
reactions that occur several hours, days or up to 
6 weeks after drug exposure. Immediate reactions 
present as urticaria, angioedema, or anaphylaxis, 
whereas for delayed reactions the clinical spectrum is 
much wider: maculopapular eruptions (the most fre-
quent reaction pattern) (Fig. 26.1), exfoliative erythro-
derma, acute generalized exanthematous pustulosis 
(Fig. 26.2), localized fixed drug eruptions, Stevens–
Johnson syndrome (Fig. 26.3), toxic epidermal necrol-
ysis (Fig. 26.4), other bullous reactions mimicking 
pemphigus vulgaris or bullous pemphigoid, vasculitis, 
and lupus erythematosus [9].
Topically applied drugs may cause contact dermati-
tis reactions or photosensitive contact dermatitis. 
Topical sensitization and subsequent systemic expo-
sure may induce skin reactions similar to systemic 
drug eruptions (maculopapular exanthema) [10] or 
patterns more typical of a systemic contact dermatitis, 
such as acrovesicular dermatitis, the “baboon syn-
drome” (see Chap. 17), or Symmetrical drug-related 
intertriginous and flexural exanthema (SDRIFE) [11, 12]. 
It is clear that in these situations patch testing can be of 
great help as a diagnostic tool [11].
Type of adverse  
reaction
Mechanisms
A – Augmented Exaggerated pharmacologic 
activity of the drug
B – Bizarrea Idiosyncratic, unpredictable, 
usually immune-mediated
C – Chemical Chemical or pharmacological 
effect of drug
D – Delayed Reactions occurring late, related 
mainly with carcinogenesis  
or teratogenesis
E – End-of-doses Reaction to drug suspension
Table 26.1 Main types of adverse drug reactions, according to 
its mechanism [7]
aThese are the ones that will be dealt with in this chapter
a
b
Fig. 26.1 Generalized maculopapular exanthema from amoxi-
cillin that developed on the ninth day of therapy, with symmetric 
lesions on the trunk (a) and targetoid lesions on the hands and 
forearms (b). This patient had positive patch tests with amoxicil-
lin and ampicillin at 1 and 10% pet. and negative tests with peni-





















































326 Patch Testing in Adverse Drug Reactions 
In patients with drug eruptions without previous 
contact sensitization, patch testing can also induce 
specific positive reactions, but the sensitivity of this 
test is much lower than in allergic contact dermatitis 
[13, 14]. The value of patch testing in CADRs has not 
always been appreciated, but there is growing interest 
in this field. It is a safe method and results can be very 
rewarding, as positive test results can be very useful to 
confirm drug imputability established on clinical 
grounds. Patch testing can also be helpful for studying 
cross-reactions and understanding pathomechanisms 




Fig. 26.2 Acute generalized exanthematous pustulosis from 
ciprofloxacin, on the third day of evolution, with coalescent pus-
tules on erythema, predominating on the main body folds 
(a). Patch tests were positive with ciprofloxacin at 10% pet. and 
also norfloxacin and lomefloxacin. The erythemato-vesicular 
reaction at D2 (b) changed into a pustular reaction at D3 (c). 
Histopathology showed an intraepidermal spongiform pustule as 
in the acute eruption
Fig. 26.3 Stevens–Johnson syndrome from lamotrigine, an anti-
epileptic drug frequently responsible for this clinical reaction 
pattern, particularly in children. Note the typical oral involve-
ment, with erosion of the whole semimucosa of the lower lip
Core Message
Drug eruptions are adverse skin reactions caused  ›
by a drug used in normal doses. They present 
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26.1.3  Pathomechanisms Involved in 
Immune-Mediated Drug Eruptions
In most CADRs of the type B there is involvement of the 
immune system. Either antibodies or T-cells with their 
specific receptor recognize the drug, or a metabolite, or 
any of these combined with a peptide or with an autolo-
gous cell. These drug reactions can be classified accord-
ing to the immunological reaction types of Gell and 
Coombs (see Chap. 3), but often it is not one isolated 
immunological mechanism that is responsible for the event: 
combinations of type I and IV hypersensitivity exist [16] and 
even more complex mechanisms can be involved [5, 17]. 
Genetic susceptibility is also important, as in cases of toxic 
epidermal necrolysis and Stevens–Johnson syndrome 
from allopurinol and carbamazepine and, particularly, 
in abacavir hypersensitivity syndrome, where HLA-
B*5701 pretesting has significantly reduced this severe 
adverse reaction [18, 19].
Immediate reactions involve mainly drug-specific 
IgE and mast cell and basophil degranulation [20], 
whereas delayed reactions after systemic drug expo-
sure depend mainly on type IV hypersensitivity reac-
tions, with previous T-cell sensitization [21, 22]. 
By the clinical pattern and time course, we can suspect 
which mechanisms can be involved, but sometimes it 
is not possible [23].
The pseudo-allergic (anaphylactoid) reactions, 
including urticaria induced by acetylsalycilic acid and 
other nonsteroidal anti-inflammatory drugs (NSAIDs) 
and angioedema induced by angiotensin conversing 
enzyme inhibitors (ACEi), are examples of nonimmu-
nological reactions mimicking a true (type I) allergic 
reaction. The most plausible explanation for these 
reactions is a nonspecific release of histamine and 
other mast cell and basophil mediators without the par-
ticipation of IgEs or a reduced capacity to metabolize 
kinins, with consequent accumulation of the potent 
vasodilator bradykinin [24].
26.1.4  T-Cell Involvement in Drug 
Eruptions
Apart from allergic contact dermatitis and systemic 
contact dermatitis, delayed type IV hypersensitivity 
has been documented in maculopapular exanthema, in 
drug hypersensitivity syndrome/DRESS, in acute gen-
eralized exanthematous pustulosis, in the localized 
fixed drug eruption, and in the more extended bullous 
reactions in a continuum from Stevens–Johnson syn-
drome to toxic epidermal necrolysis [9]. These reac-
tions usually begin within 7–21 days on the first 
exposure, but rechallenge is usually accelerated, posi-
tive with lower dose and more severe, suggesting spe-
cific immune sensitization. In the skin biopsies of the 
CADR there is mainly a dermo-epidemal infiltration of 
activated T-cells, some of which specifically recognize 
the drug or one of its metabolites. And, apart from the 
skin, drug-specific T-cells have been isolated from the 
blood or blister fluid during the acute reaction and also, 
later, from skin biopsies of positive patch tests [9, 25–28]. 
As previously referred, the clinical presentation of these 
CADRs is very heterogeneous, even though there are 
data to support the involvement of delayed type hyper-
sensitivity mechanisms [5]. Apart from other individ-
ual circumstances, this heterogeneity very probably 
depends on different pathways of drug recognition by 
the immune system and on the subtypes of effector 
T-cells. Although there is little knowledge on which 
cells participate in the process of drug presentation 
during the sensitization phase, the drug, a metabolite 
or both, can be recognized by the TCR combined with 
HLA molecules, either class I, class II, or both, with or 
without previous processing by the antigen presenting 
Fig. 26.4 Toxic epidermal necrolysis/Lyell’s syndrome induced 
by carbamazepine. Note confluent flaccid bullae on the trunk, 
already with a few areas of epidermal detachment, and atypical 
target lesions in the arms. Although this is not frequent, this 
patient had positive patch tests to carbamazepine, which on his-
tology had skin apoptosis of the whole epidermis, such as in the 








































































526 Patch Testing in Adverse Drug Reactions 
cell [29]. There are many studies on the effector T-cells 
(Th1, Th2, Tcit) and on the main cytokines and 
chemokines involved in the final reaction (IFN-gama, 
IL-8, IL-5, eotaxin, TNF-alfa, Fas) [22, 30]. Recently, 
subtypes of type IV hypersensitivity have been defined 
in the participation of CADR [22, 31]. A Th1 pattern 
with IFN-gama production, considered a type IVa 
hypersensitivity, is mainly involved in allergic contact 
dermatitis and maculopapular exanthema. Type IVb 
involves mainly a Th2 response, with IL-5 and eotaxin 
production and, consequently, eosinophil recruitment 
and activation. Actually, there is eosinophil infiltra-
tion in the dermis in maculopapular exanthema, and 
systemic eosinophilia is one of the criteria for drug 
hypersensitivity syndrome/DRESS [17, 32, 33]. In 
acute generalized exanthematous pustulosis, T-cells 
isolated from the blood and the skin produce high 
amounts of the chemokine CXCL8 (IL-8) and 
GM-CSF, with consequent preferential neutrophil 
recruitment that is responsible for the epidermal 
spongiform pustule typical of this CADR (type IVd 
hypersensitivity) [34, 35]. Type IVc, with predomi-
nant T-cell cytotoxic activity, is involved at a lower 
level in maculopapular exanthems, but is very pro-
nounced in Stevens–Johnson syndrome and toxic epi-
dermal necrolysis, where keratinocyte apoptosis is the 
hallmark of the reaction [22, 36, 37]. Fixed drug erup-
tions are also typical T-cell-mediated reactions, with a 
special localization pattern and a very particular reten-
tion of drug-specific T-cells in lesional areas. These 
resting T-cells are activated very shortly after topical 
or systemic drug exposure, and produce high amounts 
of IFN-gama and cytotoxic mediators (TNF-alfa and 
Fas), but precocious infiltration of regulatory T-cells 
(Tregs) seems to prevent its evolution to the more 
severe bullous reactions [38, 39]. Delayed type hyper-
sensitivity is also involved in some photosensitive 
drug reactions, mainly in those with an eczematous 
pattern [40–42].
Therefore, the participation of drug-specific T-cells 
in several drug eruptions other than allergic contact 
dermatitis makes patch testing suitable for their study. 
Nevertheless, the rate of negative reactions is much 
higher, as mechanisms other than T-cell-derived hyper-
sensitivity are involved, often in a more complex 
 interplay with other systemic inflammatory reactions 
(viral infections, autoimmune diseases). Also in some 
CADRs, very probably, the allergen is not the drug 
itself, but a systemic metabolite and, although skin 
metabolism is quite efficient, some drugs are not 
metabolized by skin cells [43]. And there are certainly 
other reasons, not completely understood, to explain 
many negative patch tests.
26.2  The Workup in the Diagnosis  
of an Immune-Mediated CADR
26.2.1  Clinical Diagnosis  
and Drug Imputation
The diagnosis of a drug eruption is easier if we are fac-
ing a clinical pattern typical of a CADR, such as a 
fixed drug eruption, a toxic epidermal necrolysis, or a 
generalized exanthematous pustulosis. In nonspecific 
skin reactions patterns, a particular workup has to be 
done to exclude other causes for the rash, such as a 
viral infection in maculopapular exanthema or a non-
drug allergen in acute urticaria or angioedema. In these 
situations, the diagnosis of drug eruption can be a 
diagnosis of exclusion.
In severe CADR, such as toxic epidermal necroly-
sis, DRESS, and acute generalized exanthematous 
pustulosis, complementary tests are needed to evaluate 
the degree of systemic involvement.
At the time of diagnosis, it is extremely important 
to identify the culprit drug. In most CADRs, improve-
ment depends on the drug suspension and prognosis 
depends mainly on an early drug withdrawal.
Imputation of the culprit drug is performed mainly 
on clinical grounds, based on extrinsic and intrinsic 
criteria. Extrinsic criteria include all previous reports 
of such a CADR. Intrinsic criteria are mainly based on 
the chronology and clinical characteristics of the 
adverse event: the clinical pattern of the eruption, its 
chronological relation with the initiation and suspen-
sion of the drug, and information on previous drug 
exposure, with or without reaction (accidental rechal-
lenge) [44, 45]. No single complementary test can 
replace a good characterization of these parameters. 
Core Message
Many delayed drug eruptions are T-cell-  ›
mediated and, therefore, patch testing can be 
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But, even in the cases where very accurate data are 
available, the imputability or causality index for a sin-
gle drug can be very low: many patients who develop a 
CADR are on multiple drugs; any drug can induce a 
drug eruption; different drugs can induce the same 
clinical pattern of drug eruption; and, the interval 
between drug initiation and development of the CADR 
can vary widely (6 h up to 6 weeks), even considering 
only delayed reactions (Table 26.2).
26.2.2  Complementary Tests  
to Confirm Drug Imputation
Drug reintroduction is considered the more definitive 
test for confirming the culprit drug, but it does not 
always reproduce the skin reaction [45, 46]; it is time-
consuming when several drugs are suspected and it is 
contraindicated in severe reactions, such as toxic epi-
dermal necrolysis or drug hypersensitivity syndrome/
DRESS [45]. Therefore, complementary clinical and 
laboratory investigations have to be conducted in order 
to try to confirm, or deny, an imputable drug.
Laboratory tests, such as specific IgE or basophil acti-
vation, are used for the study of immediate reactions, 
and lymphocyte transformation tests (LTT) or lymphocyte 
stimulation tests (LST) are used for studying mainly 
delayed hypersensitivity reactions [47]. They can help in 
the diagnosis, with the advantage of being an in vitro 
method that, in some circumstances, can be performed 
during the acute phase. Nevertheless, these tests are not 
available for most drugs, procedures are not standard-
ized, results are inconsistent with undetermined sensitiv-
ity and specificity, and therefore, they are not performed 
on a routine basis [23, 47].
Skin testing can be used later, after the resolution of 
the CADR. It is important to choose the most adequate 
skin test, according to the reaction pattern, even though 
this is not always so straight. (Table 26.2) Tests with 
immediate readings, such as prick, scratch, or intrader-
mal (i.d.) tests, are advised for immediate reactions 
such as urticaria and angioedema, whereas tests with 
delayed readings, such as the patch test, are mainly rec-
ommended for delayed skin reactions, e.g., eczematous 
reactions, maculopapular exanthema, erythroderma, 
drug hypersensitivity syndrome/DRESS, acute gener-
alized exanthematous pustulosis, fixed drug eruption, 
Stevens–Johnson syndrome, and toxic epidermal 
necrolysis [15, 48]. Prick and i.d. tests with late read-
ings, performed when patch tests are negative, may 
increase the effectiveness of skin testing. In two 
CADR pattern Expected free interval Most adequate test to perform
In vivo In vitro
Urticaria/angioedema anaphyalxis Minutes to 1 h Prick, i.d.a IgE (RAST/CAP)
Oral challengeb Basophil activation
Maculopapular exanthema 7–21 days Patch, i.d.a LST/LTT
2 daysc Oral challenge
Drug hypersensitivity/DRESS 3–6 weeks Patch i.d.d LST/LTTe
Acute generalized exanthematic  
pustulosis






Fixed drug eruption 6–24 h Lesional testing
Systemic photosensitivity 2 days Photopatch test
Oral photoprovocation
Table 26.2 Main CADRs and the most adequate skin test according to each clinical pattern
aPerform i.d. tests only if prick or patch tests are negative
bNot adequate in cases of anaphylaxis or severe angioedema
cOn drug reintroduction
di.d. is not advised, on a first basis, due to a possible severe reaction





































































726 Patch Testing in Adverse Drug Reactions 
separate studies these tests improved the diagnosis by 
about 10% in nonimmediate reactions from aminopeni-
cillins and synergistins [49, 50]. Commercial material 
for i.d. testing is not available for most drugs and, there-
fore, it has to be prepared, on a patient basis, in a steril-
ized setting, which is not always feasible. Moreover, in 
case of positive results, it may be difficult to use con-
trols to evaluate the specificity of the reaction, Also, it 
is recommended to perform i.d. testing in a hospital set-
ting, particularly in the study of severe CADRs [51].
When positive, in vitro or in vivo tests can be of 
help in confirming which drug was responsible for the 
CADR, but, on the contrary, these tests are very sel-
dom able to exclude the involvement of a drug.
26.3  Patch Testing in CADRs
26.3.1  The General Value  
of Patch Testing
Patch testing in the study of drug eruptions has been 
performed for many years, but not as a systematic inves-
tigation in large multicenter investigational studies. 
There are a few studies with a relative large number of 
patients patch tested with drugs [13, 51, 52] and they 
include a wide variety of patterns of drug eruptions. 
Nevertheless, the inclusion criteria are quite different 
and the imputability/causality index for the drugs 
 studied (very probable/probable/possible) is not known 
in most cases. Also, as there are so many patterns and so 
many responsible drugs, it is difficult to ascertain the 
patch test reactivity and its real value (sensitivity and 
negative predicative value) in the many different 
settings.
While considering a wide range of drug eruptions, 
the frequency of positive tests varies from 7.5 to 54% 
[13, 14, 51–54]. Apart from patient selection, patch 
test reactivity depends mainly on the clinical pattern of 
the drug eruption and the drugs involved [51–54].
Patch tests are mostly positive in eczematous erup-
tions, systemic contact dermatitis, maculopapular, and 
erythrodema, and particularly, in more severe reactions 
[12, 14, 20, 51, 53, 55] (Table. 26.3).
In acute generalized exanthematous pustulosis there 
are many reports with positive patch tests, but with a 
few cases each [8, 26, 34, 35, 55–59]. In their study, 
Wolkenstein et al. found 50% of positive tests (7+out 
of the 14 patients tested) [60]. In this CADR, patch 
tests can show a pustular reaction with an epidermal 
spongiform pustule on skin biopsy, as in the acute 
reaction [26, 35, 56, 61] (Fig. 26.2b, c).
CADR pattern Number positive tests/number patients tested (%)
Osawa et al. [52] 
(n = 197)
Barbaud et al. [51] 
(n = 72)
Lammintausta et al. [13] 
(n = 826)
Other studies
Maculopapular 10/72 (14) 16/27 (59) 81/785 (10.3) 33/61 (54) [14]
Erythroderma 8/15 (53) 5/7 (71)
Eczematous 9/17 (53) 3/9 (33)
Erythema multiforme 6/29 (21)
Lichenoid 2/11 (18)
Photosensitivity 4/4ª (100) 2/12 (16.7)
Fixed eruptions 2/6 (33) 0/3 8/28 (28.6) 26/30 (87) [68]
Urticaria/angioedema 2/18 (11)
AGEP 7/14 (50) [60]
SJS/TEN 2/22 (9) [60]
Miscellaneous 15/47 (32) 1/6b (17)
Total 62/197 (31) 31/72 (43) 101/826 (12.2)
Table 26.3 Patch test results according to the type of eruption (adapted from Osawa et al. [52] Barbaud et al. [51] and Lamminatausta 
and Kortekangas-Savolainen [13])
aPhotopatch test
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In DRESS, patch tests are often positive with aba-
cavir [19, 62, 63] and antiepileptics, particularly car-
bamazepine [17, 64, 65] (Fig. 26.5). Patch test reactivity 
is much lower, below 10%, in Stevens–Johnson syn-
drome or toxic epidermal necrolysis [55, 60]. In some 
occasions histopathology of the patch test can also 
reproduce the full thickness epidermal apoptosis, such 
as in the acute reaction.
Fixed drug eruptions are unique in the persistence 
of drug-specific T-cells in residual skin lesions, so we 
can expect to find positive tests on the these lesions, 
in a high percentage of cases [66–68], particularly, 
in fixed drug eruptions from NSAIDs [66, 69, 70] 
(Fig. 26.6). Alanko found as many as 26 positive tests 
out of 30 (87%) [68].
In photosensitive eruptions, when it is not a clearly 
phototoxic reaction, photopatch tests can be rewarding 
in the study of systemic photosensitivity as in photoal-
lergic contact dermatitis [41, 42, 71, 72]. Piroxicam 
[40, 73–77], ketoprofen [71, 78], the fluorquinolones 
[42, 79, 80], and flutamide [81, 82] are examples of 
drugs that frequently elicit positive photopatch tests.
The reactivity of patch testing also depends on the cul-
prit drug. Carbamazepine induces positive patch tests in 
more than 70% of the cases of delayed drug eruptions 
[51, 65, 83–86] (Fig. 26.5). High reactivity is also 
observed with tetrazepam [35, 51, 87–89], abacavir 
[19, 62, 63, 90], aminopenicillins [13, 20, 91], cefa-
losporins [13, 92], synergistines [50], cotrimoxazole [14] 
clindamycin [13, 93–95], (Fig. 26.7) diltiazem [14, 
96–98], heparin derivatives [14, 99, 100], corticosteroids 
[101–103], pseudoephedrine [104], and hydroxyzine [14, 
105, 106]. Nevertheless, contrary to the most regularly 
referred rate of 30–40% of positive reactions to betalac-
tam antibiotics [51], in a recent review by Blanca et al., 
the rate of positive reactions was much lower (2.6%) 
[20], which is probably due to a different patient selec-
tion (Table 26.4).
The list of drugs reported to elicit positive patch or 
photopatch test reactions is increasing every day, as 
this method is increasingly being used in the diagnosis 
of drug eruptions.
Fig. 26.5 Positive reactions to carbamazepine tested at several 
concentrations (1–20% pet) in a patient with a severe exanthema 
in the context of a DRESS (drug reaction with eosinophilia and 
systemic symptoms). In this severe drug reaction it is advised to 
test carbamazepine only at 1% pet
Fig. 26.6 Lesional testing in a residual pigmented lesion of 
fixed drug eruption. Positive reaction with the NSAID, nimesu-
lide, tested at 1% pet, presenting as erythema and infiltration. 
Note the negative reaction to another NSAID, tested at the left 
side, confirming the specific nature of the reaction
Core Message
Patch tests are more frequently positive in  ›
maculopapular exanthema, acute generalized 
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26.3.2  Patch Test Technique
It can take weeks before skin reactivity can be evalu-
ated properly by patch testing. Thus, it is advisable to 
wait several weeks after the rash has gone to perform 
patch tests. It is not known exactly how long, but 
6 weeks after complete resolution of the CADR is usu-
ally advised [15, 107]. Also, we do not know for how 
long skin sensitivity persists. Although some reactions 
are lost, many patients tested after 10 years still react 
positively [49]. Therefore, it is usually recommended 
to patch test within 6 weeks to 6 months [15].
Patch testing is performed in the generally accepted 
way on the back, as in the study of allergic contact 
dermatitis. In particular cases, as in fixed eruptions, 
reactivity occurs only in skin areas where the skin 
reaction has occurred [66, 108, 109]. The application 
time is usually 2 days, but occasionally it can be con-
venient to remove tests at D1 [49]. Readings are per-
formed at D2 and at D3 or D4, and scored negative to 
3+, according to the ICDRG guidelines.
In fixed drug eruptions, test materials are applied in 
duplicate: on an inactive, residual lesion and on the 
normal back skin, which serves as a negative control. 
The residual pigmentation is a useful marker to indi-
cate the area to apply the test. Tests are usually applied 
for 1 day, with occlusion, as in patch testing. Readings 
are performed at D1 and D2, or at D3 if previously 
negative [66]. As sometimes positive reactions are seen 
only in the first 24 h, Alanko [68] prefers an open test, 
which makes observations possible during this period. 
Fig. 26.7 Positive patch tests with clindamycin, the pure sub-
stance tested at 10% in pet.(upper test), with identical results 
when testing with the smashed content of the pills of clindamy-
cin from two different brands (Dalacin C® and Clindamicina 
Atral®), both prepared at 10% in pet (lower reactions)
Culprit drug Number positive reactions/number of patients tested (%)
Betalactam antibiotics 4/24 (29) [53]
Amoxicillin 10/247 (4) [13] 7/17 (41.2) [51]
Cefalosporins 12/220 (4.1%) [13]
Pristinamycin 7/8(87) [51] 17/20 (85) [13]
Trimethoprim 10/163 (6.2%) [13]
Cotrimoxazole 4/140 (2.9) [13]
Clindamycin 12/63(19) [13] 5/33 (15) [94] 8/26 (31)a
Aciclovir 2/8(25) [45]
Abacavir 7 [63]b
Carbamazepine 6+/7 (86) [53] 13/17 [64]
Diltiazem 3/9(33.3) [13] 7/13 (54) [98]
Allopurinol 1/10 (10) [13] 0/19 [64]
Pseudoephedrine 5/16 (31.2) [13]
Piroxicam (Photo) 75/82 (91.4) [73]
Table 26.4 Patch test results in delayed CADR, according to the culprit drug
aPersonal data 
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A reaction is regarded as positive, if it occurs only in 
the residual lesion, and when clear erythema is visible 
for at least 6 h. Often there is erythema with infiltration 
(Fig. 26.6), eczema, or a bullous reaction that mimics 
the histopathology and clinical pattern of the acute 
fixed drug eruption [66, 70]. The reaction occurs exclu-
sively in the area of application of the test or reactiva-
tion of the whole residual lesion can occur [66].
In systemic drug photosensitivity photoepicutane-
ous patch tests are performed, as in photoallergic con-
tact dermatitis, using mainly UVA irradiation, at a dose 
of 5 J/cm2 [41, 110, 111] (see Chap. 29).
26.3.3  Material for Patch  
Testing with Drugs
26.3.3.1  Patch Testing with Pure Drugs
In recent years, with the increasing interest in patch 
testing in drug eruptions, several firms that prepare 
allergens for the study of contact allergy are also pro-
ducing standardized drug allergens with the pure active 
products. Of course, there is only a very limited number 
of drug allergens and every drug can induce a CADR. 
Nevertheless, the list includes drugs more frequently 
responsible for delayed CADRs: antibiotics, antiepi-
leptic, NSAIDs, and some isolated drugs (Table 26.5). 
No controls are needed for these allergens, as many 
patients, who have been exposed to the drug with no 
reaction and, also nondrug exposed subjects, have been 
tested with no reaction.
This makes patch testing with drugs simple, allows 
testing several drugs at the same time and, particularly, 
testing with analogous chemicals to study cross- 
reactions and find possible replacement drugs. Actually, 
these studies have shown very interesting data on pat-
terns of cross-reactivity that may be very informative 
for the patient and the doctor.
But, these commercialized drug allergens might be 
improved, as it is not known yet if the most correct 
concentrations or the most adequate vehicles are being 
used. Recommended concentrations are usually between 
1 and 20% of the pure chemical, doses that are usually 
higher than in the study of allergic contact dermatitis. 
But for drugs, such as carbamazepine, low concentra-
tion, 1% or even below, can be enough [86, 112] 
(Fig. 26.5). Increasing concentration above 1 or 5% 
pet. does not always increase patch test reactivity, as 
shown for carbamazepine and amoxicillin [49, 112]. 
For the 20% concentration, carbamazepine, hydro-
chlorotiazide, propanolol, sulphametoxazol, and 
thrimetoprim did not evoke reactions either when 
tested in 200 volunteers [1], or in previously exposed 
patients [65]. Although reactivation of the CADR dur-
ing patch testing is exceptional [65] [144], in the case 
of a severe drug eruption, it is advisable to start with 
lower concentrations [15].
Also, there is not enough data on the best vehicle to 
perform patch testing. Most chemicals react when pre-
pared in petrolatum, but in some cases water, ethanol, 
or acetone may be more adequate, as in the case of 
estradiol [10], or DMSO may be necessary to solubi-
lize cotrimoxazole and its constituents [55, 113].
26.3.3.2  Patch Testing with Drugs  
Used by the Patient
If the pure drug is not available, which is often the 
case, patch testing can be done with the drug used by 
the patient, either a tablet, a capsule, or the solution for 
oral, i.v., or i.m. use. The amount of active drug in a 
tablet varies and can be very low. Therefore, it is pref-
erable to use the content of a capsule or the powder for 
parenteral use, which usually have more active drug. 
This powder, or the fine powder obtained from smash-
ing the pill after removing the external coating, can be 
diluted in petrolatum and water, or other vehicles, in a 
way to have the active drug in the final concentration at 
10% (Fig. 26.7). If the concentration of the active drug 
is too low, it is recommended to prepare the smashed 
powder of the pill at 30% [15]. Of course, in this 
method, the final concentration of the active drug can 
vary a lot, but 30% is the highest concentration to 
obtain a homogenous preparation [15].
When tests are positive with these preparations, it is 
recommended to have serial dilutions and it is obliga-
tory to test, at least, ten controls, preferably previously 
exposed individuals who have given their informed 
consent.
Even when tests have been done with pure chemi-
cals, it can also be worthwhile to perform tests with the 
filler materials and the original drug preparation. In 
principle, reactions to the “inert” filler substances and 





























































































1126 Patch Testing in Adverse Drug Reactions 
Group of drugs Drug allergen Concentration vehicle (% pet) Company
Antibiotics Penicillin G, potassium salt 10 CD
Ampicillin 5 MT
Amoxicillin trihydrate 10 CD
Dicloxacillin sodium salt hydrate 10 CD
Cefradine 10 CD
Cefalexin 10 CD
Cefotaxim sodium salt 10 CD
Doxycyclin monohydrate 10 CD
Minocycline hydrochloride 10 CD
Erythromycin base 10 CD MT





Ciprofloxacine hydrochloride 10 CD
Clindamycin phosphate 10 CD
Antiepileptics Carbamazepine 1 CD
Hydantoin 10 CD
NSAIDs Acetylsalicylic acid 10 CD MT
Diclofenac sodium salt 1 CD Bi MT
Ketoprofen 1 CD Bi Mt
Naproxen 5 Bi MT
Piroxicam 1 CD Bi MT
Acetaminophen 10 CD Bi
Ibuprofen 10 CD Bi MT
Miscellaneous Acyclovir 10 CD
Hydrochlorothiazide 1 and 10 CD
Diltiazem hydrochloride 10 CD
Captopril 5a CD
Table 26.5 Commercially available drug allergens for patch testing
CD chemotechnique diagnostics, Malmö Sweden
MT Martí Tor, Dermatitis de Contacto, Barcelona, Spain
Bi Bial Aristégui, Bilbao, Spain
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26.3.4  Safety of Patch Testing
The risk of reactivation of the drug eruption is very low 
[14, 118], even in serious delayed CADRs [64], but it has 
been occasionally reported with acyclovir, pseudoephed-
rin, pristinamycin [51], and carbamazepine, particularly 
when testing with the powder of the pills [119].
Serious immediate reactions evoked by patch test-
ing are rare and have been described mainly in the 
study of anaphylaxis [120–122], particularly with pen-
icillins, neomycin, or bacitracin. For safety reasons, it 
is practical to observe the patient for approximately 
half an hour after application of the test material.
The risk of patch testing is considerably lower com-
pared with i.d. tests. Thus, the patch test is a good test to 
start with. If negative and, for the particular patient, it is 
important to prove the causality of the drug, the study 
can continue with the sequential use of prick, scratch, 
and i.d. tests with a delayed reading [15]. If all are nega-
tive, as a next step, a provocation test can be performed 
in a hospital setting, except if there is a contraindica-
tion, namely, a previous severe reaction, such as DRESS 
or toxic epidermal necrolysis, or the involvement of 
drugs as antiepileptics or salazosulfapyridine [45].
Another adverse patch test effect is sensitization by 
patch testing; this is rarely seen, even with penicillins 
[123].
26.3.5  Specificity of Patch Test Reactions
Positive patch test reactions, performed according to the 
recommendations [15], have been shown to be highly 
specific. Histopathology of drug patch tests is often anal-
ogous to the acute reaction [61, 124] and some 
T-cells that infiltrate the skin, in the patch test, specifically 
recognize the drug [25–28, 34]. Actually, drug-specific 
T-cells, with phenotypic and functional charac teris tics 
similar to those isolated from the blood or the skin during 
the acute phase of the CADR, have been isolated from 
positive patch tests with several drugs, such as amoxicil-
lin, carbamazepine, lamotrigine, sulfonamides, fluorqui-
noles, and tetrazepam [25–28, 34, 35].
Patch testing with pure drugs or with low concentra-
tions of the commercial products rarely yields false 
positive reactions. But, occasionally, constituents of 
the excipient of the commercial drug can cause false 
positive reactions due to irritation or low pH or they 
can induce a nonrelevant positive patch test reaction in 
a previously contact sensitized patient [114]. For 
instance, false positive results have been observed with 
the powder of the pills of spironolactone (Aldactone®), 
colchicine, captopril (Lopril®), cloroquine (Nivaquine®), 
celecoxib (Celebrex®) tested at 30% pet, and with 
omeprazole (Mopral®) tested at 30% aq. [14, 55, 114].
False-negative reactions can be expected due to tech-
nical problems of the patch tests (low concentration or 
wrong vehicle, deficient skin penetration, wrong timing 
for performing patch testing), but there are certainly 
many other explanations for the absence of skin reactiv-
ity on patch testing: the responsible hapten is a drug 
metabolite that is not formed in the skin, the CADR is 
not an immune reaction or not dependent on the delayed 
hypersensitivity or, apart from drug exposure, concomi-
tant factors (viral infection or concomitant drugs) are 
necessary for enhancing drug hypersensitivity [91].
For cotrimoxazol and acyclovir, patch tests in pet-
rolatum are often negative, and DMSO or other pene-
tration enhancers may be necessary to have positive 
patch tests. There is, for the moment, no explanation 
for the negative patch tests to allopurinol in delayed 
CADRs, presumed to be immune-mediated, even when 
there is a positive accidental rechallenge. Although 
there is one report of a positive test in the study by 
Lammintausta and KorteKangas-Savolainen [13], in 
our experience, with more than 30 patients now, we 
did not observe a positive patch test with allopurinol, 
using low or high concentrations (1–20%), petrolatum 
or ethanol as excipient, with or without tape stripping, 
or even using one of its metabolites (8-oxypurinol) in 
different concentrations and vehicles [125].
26.3.6  Evaluating Cross-Reactivity  
on Patch Testing
Cross-reactivity observed among drugs in CADRs can 
be studied, sometimes with very interesting results, at 
the patch test level.
It has been shown, in maculopapular exanthema, that 
amoxicillin and ampicillin always cross-react [54, 112], 
and this cross-reactivity is neither often extensive to 
benzilpenicillin or carbopenens [20], nor to cefa losporins 
except, eventually, cefalexin [126]. A similar pattern is 
usually confirmed by oral challenge [20, 49]. There is 


























































































1326 Patch Testing in Adverse Drug Reactions 
and the fluorquinolones [30] and between pristinamycin 
and virginiamycin [50]. On the other hand, absence of 
cross-reactions between tetrazepam and other benzodi-
azepines, particularly diazepam, was confirmed by patch 
testing and oral provocation [89, 127].
Cross-reactions in fixed drug eruptions were also 
found among different sulfonamides, among the three 
piperazine derivatives (hydroxyzine, cetirizine, and levo-
cetirizine) [128], and oxicams (tenoxicam and piroxi-
cam) [66, 70]. This pattern of cross-reactivity between 
piroxicam and tenoxicam, observed in all cases of fixed 
drug eruptions studied, does not occur in other patterns 
of CADR from oxicams. In patients with photosensitiv-
ity from piroxicam, tenoxicam is safe, as shown by pho-
topatch testing and drug challenge [40, 66].
Another particular pattern of cross reaction was shown 
in photopatch tests between the arylpropionic NSAIDs, 
ketoprofen, suprofen, and tiaprofenic acid in photoaller-
gic contact dermatitis, and the lipid lowering agent, feno-
fibrate, in systemic photosensitivity [111, 129].
Unfortunately, there is not always correlation 
between cross-reactivity in patch testing and oral prov-
ocation, as in patients who react only to carbamazepine 
in the patch test, but do not tolerate other aromatic 
antiepileptics [65].
26.4  Conclusions: Interpretation  
of Patch Test Results
Patch tests results in the study of drug eruptions should 
be interpreted very carefully.
A positive test, using nonstandardized products, has to 
be checked in controls to exclude false positive reactions. 
A true positive test can be regarded as a sign of immuno-
logical reactivity of the patient and should be taken seri-
ously, if compatible with the history. Readministration of 
the drug should be avoided as it can again elicit an adverse 
reaction, usually, a more severe one.
A negative test result does not exclude hypersensi-
tivity or an adverse drug reaction. The test method 
might not be adequate due to another pathomechanism, 
the bioavailability of the test material might have been 
insufficient, the wrong drug may have been tested (his-
tory and drug records can be surprisingly inaccurate), 
or the right drug may have been tested but the allergen 
could be a metabolite. Thus, a negative test result does 
not allow a definitive conclusion.
If necessary, other tests have to be performed, such as 
prick, scratch and intradermal skin tests or a challenge 
(provocation) test [48]. In vitro tests for IgE (RAST) 
exist for some drugs, as well as lymphocyte stimulation/
transformation tests. However, these tests are rarely 
available or performed on a routine basis and their sen-
sitivity and specificity has yet to be precisely evaluated.
In conclusion, although many suspected patients 
have negative reactions, it remains worthwhile to per-
form patch tests in patients with delayed CADRs. They 
can confirm a clinical imputability and avoid an even-
tual drug reintroduction with more severe conse-
quences. In very particular cases, they can also give 
important information on cross-reacting drugs.
26.5  Classic Articles and Monographs
Barbaud A, Gonçalo M, Bruynzeel D, Bircher A 
(2001) Guidelines for performing skin tests with drugs 
in the investigation of cutaneous adverse drug reac-
tions. Contact Derm 45:321–328.
In detail is described how to perform skin tests in 
CADRs. The presented guidelines are proposed by the 
Working party of the European Society of Contact 
Dermatitis for the study of skin testing in investigating 
CADRs.
Kauppinen K, Alanko K, Hannuksela M, Maibach H 
(eds) (1998) Skin reactions to drugs. CRC, Bocca Raton
This book gives extensive information on cutane-
ous adverse reactions and challenge tests, how to per-
form skin tests and in whom.
Pichler WJ (ed) (2007) Drug hypersensitivity. 
Karger AG, Basel
This book gives an extensive overview on the path-
omechanisms of especially type 4 allergy involvement 




Patch tests with drugs are specific and can be  ›
important to study relevant cross-reactions 
between drugs.
Core Message
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